Supply Chain
Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.
Leaders from India’s top drug makers discuss efforts to operationalize a world-class skilling institute, backed by tie-ups with organizations like the PDA, ISPE and also taking a leaf out of the automobile industry’s book to build supply chain resilience. They also exuded confidence on moving up the innovation value chain.
The efficacy of Moderna’s jab appears to fade faster than its rivals, while experts were surprised by an FDA panel’s recommendation to narrow the use of all three RSV vaccines.
The Danish drugmaker is investing over $4.1bn on a second facility in North Carolina for its GLP-1 therapies but has abandoned plans to build a new plant in Dublin, Ireland.
Indian firms accounted for over 50% of prescription volumes in five of the top 10 therapy areas in the US in 2022, as also 15% of the volume share of biosimilars, delivering savings and widening patient coverage a study by IQVIA said, while also highlighting supply chain risks that need attention.
With just 14% of active pharmaceutical ingredients estimated to be made in the US and China’s overall dominance in the space, a new study points to the pressing need for the US to address bottlenecks in the supply chain and proposes a string of approaches to partner with India in its de-risking efforts.
BioNTech and the UK government's alliance to bring personalized cancer immunotherapy to patients is making progress, but the National Health Service has to show it can deliver on clinical trials recruitment.
Quietly but unambiguously, pharma firms are accelerating their diversification away from China and are now looking to other emerging markets for growth, a strategy that reflects increasing pressures from China's volume-based procurement scheme but also US-China tensions and other geopolitical risks.
The shockwave of WuXi's withdrawal from BIO is ripping through the Chinese contract services sector. While some remain hopeful, others are preparing Plan B.
Bristol Myers Squibb’s EVP and chief digital and technology officer, Greg Meyers, tells Scrip how the company is using data, technology and artificial intelligence to speed up the clinical research process. An AI engine that leverages real-world data to improve trial diversity and promising generative AI uses cases are some of the key topics discussed.
Looking ahead on manufacturing and supply-related issues in 2024, respondents told Scrip to expect companies to bring their supply chains closer to home, improvements for delivery of cell and gene therapies, a focus by contract manufacturers and developers on sustainability and continued emphasis on access to critical drugs.
Eisai/Biogen's Alzheimer's drug will be launched in Japan on 20 December with a lower price premium than Eisai was negotiating for after back-and-forth reimbursement negotiations, and strict use and monitoring restrictions.
Astellas’s senior director, head of enterprise insights and digital solutions, digital, analytics and technology tells Scrip how data analytics and deductive hypothesis-oriented simulation are driving improved strategic decision-making across the organization. He also outlined some early generative AI use cases and the promise of digital twins in medicine.
Pointing to what it says is decreased R&D in Japan in contrast to the global market, PhRMA has again urged the country to revise its drug pricing policies and support innovation, while cautiously welcoming new moves to waive a requirement for Phase I trials in the country.
In its third annual report on fair access to prescription drugs, the US pricing watchdog found high concordance with some of its recommended policies, but thinks greater transparency is needed for a thorough assessment.
Cipla’s US business scales new peak in Q2 amid strong showing overall even as the promoter group stake sale speculation is becoming a 'distraction'. The company has new peptide assets, among others, in the wings while management also points to traction in the 'mRNA journey'.
Center for Medicare and Medicaid Innovation (CMMI) deputy director Ellen Lukens talked about the goals and challenges of a new voluntary program the agency will test with state Medicaid programs.
Drug manufacturers will have to participate in the Medicare drug price negotiation process for the foreseeable future. Judge Newman's finding that participation in Medicare is voluntary could defeat constitutional challenges to the program and have an impact on other cases.
Novo Nordisk has just become Europe’s most valuable company based on Wegovy’s huge success so far and future potential - but just how big could the obesity market get?
Big pharma valuations mostly held steady as CMS released its list of the first 10 drugs subject to Medicare negotiations under the Inflation Reduction Act, which held few surprises and included products nearing the end of their patent lives by the time negotiated pricing takes effect.